LY294002: A Benchmark PI3K Inhibitor in Cancer and Cell Signaling Research

Executive Summary: LY294002 is a potent, cell-permeable, and reversible inhibitor of class I phosphoinositide 3-kinases (PI3Ks), including p110α, p110β, and p110δ (IC₅₀ = 0.5–0.97 μM), which blocks the PI3K/Akt/mTOR signaling pathway to suppress cell growth, induce apoptosis, and inhibit autophagy (APExBIO). It is less potent but more stable and reversible than wortmannin. LY294002 also inhibits BET bromodomain proteins at micromolar concentrations. In vivo, it reduces tumor growth in mouse xenograft models at 100 mg/kg/day. Its solubility profile (insoluble in water, soluble in DMSO and ethanol) and robust use in cell culture and animal studies make it a gold-standard tool compound in cancer biology and signaling research (KU-0060648.com, Nutrients 2025).

Biological Rationale

Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that regulate cell growth, proliferation, metabolism, and survival. Aberrant PI3K/Akt/mTOR signaling is implicated in oncogenesis, tumor progression, and therapy resistance across multiple cancer types (Yu et al., 2025). Inhibition of the PI3K pathway disrupts downstream effectors including Akt and mTOR, which are critical for controlling autophagy and apoptosis. Selective small molecule inhibitors like LY294002 enable precise dissection of this pathway in both in vitro and in vivo models.

Mechanism of Action of LY294002

LY294002 (2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one) is a synthetic, ATP-competitive inhibitor that binds reversibly to the catalytic domains of class I PI3K isoforms. It exhibits the following characteristics:

• Selective inhibition of p110α (IC₅₀ = 0.5 μM), p110β (IC₅₀ = 0.97 μM), and p110δ (IC₅₀ = 0.57 μM) in biochemical assays (APExBIO).
• Blocks downstream signaling through Akt and mTOR, leading to reduced phosphorylation of substrate proteins.
• Suppresses cell proliferation and induces apoptosis in cancer cells by disrupting survival signaling.
• Inhibits autophagy by preventing autophagosome formation, a process dependent on PI3K activity.
• Inhibits BET bromodomain proteins (BRD2, BRD3, BRD4) at micromolar concentrations, modulating chromatin and gene expression.

LY294002 is cell-permeable, reversible, and exhibits greater stability than wortmannin. It does not covalently modify its targets, allowing for temporal control of inhibition.

Evidence & Benchmarks

• LY294002 inhibits proliferation of diverse cancer cell lines in a dose-dependent manner at 1–10 μM concentrations in vitro (APExBIO).
• In immunodeficient mice bearing OVCAR-3 ovarian carcinoma xenografts, daily intraperitoneal administration of 100 mg/kg LY294002 for 3 weeks significantly reduces tumor volume and cellularity (APExBIO).
• LY294002 blocks phosphorylation of Akt and mTOR in cell lysates within 30–60 min of treatment in cell culture experiments, as demonstrated by immunoblotting (internal review).
• It inhibits autophagy by suppressing autophagosome formation, as shown by reduced LC3-II accumulation in cells treated with 10 μM LY294002 (internal review).
• LY294002 reversibly inhibits PI3K activity, with rapid restoration of signaling after compound removal, unlike irreversible inhibitors such as wortmannin (APExBIO).
• In comparative studies, LY294002 shows greater chemical stability and storage tolerance than wortmannin (solid at -20°C; solutions unstable, use promptly) (APExBIO).
• LY294002 demonstrates cross-pathway inhibition of BET bromodomains, expanding its utility beyond canonical kinase inhibition (internal review).
• Natural PI3K pathway inhibitors like arctigenin also suppress cancer proliferation and induce apoptosis via similar mechanisms (Yu et al., 2025).

Applications, Limits & Misconceptions

LY294002 is routinely employed in cancer biology, signal transduction, autophagy, and epigenetic regulation studies. Its rapid, reversible inhibition profile enables kinetic experiments and pathway mapping. See this article for advanced troubleshooting; the current review extends these insights by detailing BET inhibition and workflow parameters.

Common Pitfalls or Misconceptions

• LY294002 is not a selective inhibitor for all PI3K isoforms; class II/III PI3Ks are not robustly inhibited at standard concentrations.
• It is not suitable for use in aqueous buffers; only soluble in DMSO or ethanol (≥13.5 mg/mL and ≥15.4 mg/mL, respectively).
• Prolonged solution storage leads to degradation; always prepare fresh and use promptly.
• Inhibition of BET bromodomains occurs only at higher micromolar concentrations, not at the same threshold as for PI3K inhibition.
• LY294002 is not cytotoxic to all cell types; non-malignant cells may be less sensitive, and off-target effects must be controlled for by parallel controls.

For a detailed comparison of stability and reversibility versus wortmannin, see this resource, while the present article updates practical handling and storage recommendations.

Workflow Integration & Parameters

For in vitro cell culture, LY294002 is typically used at 1–10 μM, dissolved in DMSO or ethanol. Final DMSO concentrations should not exceed 0.1–0.2% to avoid solvent toxicity. For in vivo mouse studies, daily intraperitoneal injections of 100 mg/kg over 2–3 weeks are standard for tumor suppression experiments. Store solid at -20°C and avoid long-term storage of solutions. For autophagy or apoptosis assays, pretreat cells for 30–60 minutes before analysis. For pathway validation, combine LY294002 with orthogonal tools (e.g., siRNA, alternate inhibitors). For more on experimental design, see this review, which focuses on synaptic and epigenetic contexts; the current article emphasizes cancer and proliferation models.

Conclusion & Outlook

LY294002 from APExBIO remains a gold-standard, potent PI3K/Akt/mTOR pathway inhibitor for mechanistic and translational research. Its robust performance in cell proliferation, apoptosis, autophagy inhibition, and cross-pathway epigenetic studies—combined with stability and reversibility—enable reproducible, high-impact workflows. As new PI3K and BET inhibitors are developed, LY294002 continues to serve as a critical benchmark and reference compound (product page). For more on its role in translational discovery, see this analysis; this article elaborates on quantitative benchmarks and practical considerations for modern research.